Caltec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caltec

Property Description
Active ingredient Calcitonin Salmon (Salcatonin)
Form Solution for Injection, Nasal Spray
Pharmacological class Calcium Metabolism Modifier
General purpose To slow down bone breakdown
Origin Synthetic Peptide Hormone

Caltec's Identity: Defining the Calcium Metabolism Modifier

Caltec is a medication containing the active ingredient Calcitonin Salmon (Salcatonin), which is classified as a calcitonin drug. This substance functions as a Calcium Metabolism Modifier. It is specifically a synthetic polypeptide hormone, a chemically manufactured version of the natural peptide found in salmon, classifying it as a biologic drug. Pharmacological studies have widely confirmed the superior potency and prolonged action of Calcitonin Salmon compared to its human counterpart, establishing it as a preferred antiresorptive agent in this class. Other well-known trade names containing this same formulation include Miacalcin and Fortical.


Composition, Form, and General Purpose

The core medication is a single-entity product, consisting solely of the active ingredient Calcitonin Salmon dissolved in an aqueous solution base. It is characteristically supplied in two principal dosage forms: a Solution for Injection (intended for subcutaneous or intramuscular use) and a specialized Nasal Spray (for intranasal use). This dual availability, encompassing both parenteral and mucosal routes of administration, is a key differentiating feature, offering flexibility that addresses patient compliance and clinical requirements.

The primary function of Caltec is to help regulate mineral balance by acting as an antiresorptive agent, which is clinically recognized for its role in managing conditions associated with accelerated bone turnover. It achieves this by serving as a highly specific Calcitonin Receptor Agonist, which directly suppresses the activity of osteoclasts—the cells responsible for bone dissolution. Calcitonin directly decreases the rate of bone resorption. This action is essential for conserving existing bone density and maintaining overall skeletal integrity, providing a means to stabilize the mineral environment.

What side effects are possible with Caltec?

Possible Side Effects and Safety Information

The safety profile of Caltec (Calcitonin Salmon) is characterized by adverse reactions and critical safety constraints as formally documented by regulatory agencies such as the FDA and EMA.

Adverse Reaction Classifications

Side effects are classified by their frequency and the physiological systems affected. Reactions listed as Very Common in official documents (occurring in more than 1 in 10 patients) include nausea (with or without vomiting) and flushing of the face and upper body. These effects are often most noticeable upon the initiation of therapy and tend to lessen with continued use. Uncommon effects (1/1,000 to 1/100) include dizziness, metallic taste, diarrhea, and localized reactions at the injection site.

Serious Adverse Reactions and Constraints

The label defines specific serious adverse reactions and safety constraints. The risks of Hypersensitivity Reactions, including potentially fatal anaphylaxis, are listed as critical safety warnings. The medication is also associated with an increased risk of malignancy documented with long-term use (use exceeding one year), particularly with the nasal spray dosage form. Furthermore, pre-existing hypocalcemia (low calcium levels) must be corrected before treatment is started. For the nasal spray formulation, periodic nasal examinations are recommended due to the potential for nasal mucosal alterations, ulceration, and nosebleeds.

Overdose and Emergency Response

Caltec Overdose and When to Seek Help

The authoritative information regarding the overdose profile for the substance named Caltec is not publicly available in official governmental regulatory documentation from agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

When official product labeling is available, the overdose section provides critical, fact-checked information strictly defining the risks, symptoms, and required emergency responses. This is the cornerstone of safe product use and a vital part of patient education.

Overdose Safety Summary

Overdose scope Official regulatory statement
Documented presentations Not specified in official regulatory documents for Caltec.
Physiological systems affected Not specified in official regulatory documents for Caltec.
Dose-related factors Not specified in official regulatory documents for Caltec.

Required Emergency Actions

In the event of suspected overdose or exposure to any unknown substance, the critical action remains seeking immediate medical attention. This involves contacting local emergency services or a national poison control center for guidance. Regulatory guidelines for all medicines consistently emphasize that severe symptoms or sudden, unexpected changes in health status require urgent professional evaluation in an emergency setting.

Always provide the health care professional with all available information about the substance, dose, and time of exposure to ensure rapid and appropriate management. Reliance on the full, official prescribing information is essential for all regulated health products.

Therapeutic Uses of Caltec

Therapeutic Indications and Mechanism

Caltec is a medication primarily utilized in the management of cardiovascular conditions, specifically essential hypertension and chronic stable angina pectoris. It belongs to the class of medications known as calcium channel blockers, which act by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells.

Management of Hypertension

The primary use of Caltec is the treatment of high blood pressure. By relaxing the smooth muscles in the arterial walls, the medication reduces peripheral vascular resistance. This process allows blood to flow more easily through the vessels, leading to a sustained lowering of systemic blood pressure. Effective management of hypertension is a critical factor in reducing the long-term risk of cardiovascular complications.

Treatment of Chronic Stable Angina

Caltec is indicated for the symptomatic relief of chronic stable angina. It works through two main pathways to improve myocardial oxygen balance:

  • Peripheral Vasodilation: By reducing the total peripheral resistance (afterload) against which the heart pumps, it lowers myocardial energy consumption and oxygen requirements.
  • Coronary Vasodilation: It dilates the main coronary arteries and arterioles, increasing the oxygen supply to the heart muscle. This is particularly beneficial in preventing the chest pain associated with physical exertion or emotional stress.

Clinical Benefits and Protection

The integration of Caltec into a treatment plan aims to provide continuous vascular protection throughout a 24-hour period. Because of its gradual onset of action, the medication helps maintain stable blood pressure levels without causing rapid fluctuations. For patients with angina, the benefit lies in the reduction of ischemic episodes and an increased capacity for physical activity, thereby improving overall functional stability.

Eligibility and Restrictions for Use

Caltec (a combination product potentially containing ingredients such as calcium and Vitamin D, or used as a topical ear preparation in other formulations) is generally safe for many individuals when used as directed. However, its suitability depends heavily on the specific formulation being used and the user's underlying health conditions.

Consult a Healthcare Provider Before Use

Certain individuals should consult a healthcare provider to ensure Caltec is appropriate for their specific circumstances. This includes:

  • Pregnant or Breastfeeding Women: Safety data for some formulations may be limited, and a doctor can assess the benefit-risk ratio.
  • Individuals with Existing Medical Conditions: Patients with conditions affecting calcium regulation, such as hypercalcemia (high calcium levels), hypervitaminosis D (high Vitamin D levels), kidney stones, or severe kidney disease, should seek medical advice.
  • Those Taking Other Medications or Supplements: Caltec's components, particularly calcium, can interact with certain prescription and over-the-counter medicines, affecting their absorption or efficacy.

Contraindications

Caltec should typically be avoided by:

  • Anyone with a known allergy or hypersensitivity to any of the active ingredients or excipients in the specific Caltec formulation.

What should I know about interactions with other medicines?

The official regulatory documentation for Caltec (Calcitonin Salmon/Salcatonin) notes that formal studies designed to test drug interactions have not been widely performed. Despite this, specific interactions related to the drug’s action as a Calcium Metabolism Modifier are documented.

Documented Interaction Patterns

Exposure-Altering Interactions

Co-administration with lithium may lead to a reduction in plasma lithium concentrations. This interaction is described in regulatory sources as resulting from an increased urinary clearance of lithium.

Pharmacodynamic Interactions

  • Bisphosphonates / Diphosphonates: The use in combination may result in an additive calcium-lowering effect. Additionally, regulatory labels note that prior use of diphosphonates in patients with Paget's disease may reduce the anti-resorptive response.
  • Cardiac Glycosides and Calcium Channel Blocking Agents: Co-administration requires careful attention due to the potential for these agents’ effects to be modified by changes in cellular electrolyte concentrations.

Population-Specific Note

Caltec is almost exclusively degraded in the kidneys, and regulatory documents state that metabolic clearance is much lower in patients with end-stage renal failure, constituting a population-dependent change in exposure. No specific timing-based separation rules or explicit contraindications due to interaction are formally listed.

Mechanism of Action

Caltec (Calcitonin Salmon/Salcatonin) modulates bone metabolism by selectively engaging the Calcitonin Receptor (CTR). This receptor is a G-protein coupled receptor (GPCR) found primarily on the surface of osteoclasts, the cells responsible for bone resorption. The drug functions as a full agonist, binding to the CTR and initiating an immediate intracellular cascade. This cascade involves a rapid, transient increase in cyclic adenosine monophosphate (cAMP) within the osteoclast. This molecular event causes the osteoclast to quickly lose its characteristic ruffled border, leading to the functional inactivation of the cell. This mechanistic domain achieves a swift and functional suppression of bone resorption at the tissue level.

Following osteoclast inactivation, the downstream consequence is a reduction in the rate at which calcium and phosphate are released from the skeleton into the bloodstream. Caltec's mechanism reduces skeletal output, influencing systemic mineral dynamics. A secondary mechanism, mediated by CTR activation in renal tubules, promotes the transient urinary excretion of these ions.

Dosage and Administration Information

How Caltec is Used

Caltec (Calcitonin Salmon) is administered through specific methods and schedules for its approved uses. The general principle guiding its use is to limit the total duration of treatment to the shortest possible time using the minimum effective dose.


Administration and Dosage Patterns

The medicine is available as a Solution for Injection and a Nasal Spray, defining the possible administration routes. The injectable form is given subcutaneously (SC) or intramuscularly (IM), and the intravenous (IV) route is reserved for treating severe hypercalcemia.

  • For Postmenopausal Osteoporosis, the common regimen is 200 IU via nasal spray once daily, utilizing one nostril per day and alternating the nostril daily. The injectable dose for this use is typically 100 IU administered SC or IM daily or every other day.
  • For Paget's Disease of Bone, the starting dose is 100 IU SC or IM daily. The standard pattern for long-term use involves the dose being subsequently reduced (titrated) to a maintenance level, such as 50 IU daily or 50–100 IU every one to three days, based on the specific response.
  • For Hypercalcemia, the starting dose is 4 IU/kg SC or IM every 12 hours, with the option to increase to a maximum of 8 IU/kg every six hours for unresponsive cases.

Special Procedural Requirements

Use of Caltec for both Postmenopausal Osteoporosis and Paget's Disease is conditional upon the intake of adequate supplemental calcium (minimum 1000 mg elemental/day) and Vitamin D (minimum 400 IU/day). When the injectable solution is administered, sites must be rotated regularly. For IV administration, the product requires dilution in 500 mL of 0.9% sodium chloride and slow infusion over at least six hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Caltec


1. Evidence for Use in Postmenopausal Osteoporosis

Research for Caltec primarily involved Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These trials monitored outcomes in women who are at least five years past menopause. The trials examined skeletal structure, primarily tracking measured values of Bone Mineral Density (BMD) at the spine. Researchers also tracked the incidence of new vertebral compression fractures that occurred during the study periods. Research also explored outcomes related to acute pain associated with recent vertebral fractures.

Reported findings describe patterns related to the maintenance of BMD in the spine across observed time intervals. However, evidence related to non-vertebral fracture outcomes (such as hip fractures) is considered inconsistent or unconfirmed across the overall data set. Furthermore, the reported patterns for BMD maintenance were sometimes small in magnitude, and long-term effects are not fully established.


2. Evidence for Use in Paget's Disease of Bone

Caltec was evaluated in controlled clinical trials and observational studies focusing on Paget's disease. These studies explored outcomes related to systemic imbalance, specifically monitoring key biomarkers of bone turnover (such as alkaline phosphatase), and examined changes in bone pain.

Findings reported how abnormal bone biomarkers changed, often describing patterns related to normalized levels. Studies also monitored for the development of diminished responsiveness, where the initial measured change in biomarkers may diminish or cease over continued use, as described in research. Comparative evidence against newer agents is lacking, and the potential for a diminished response is a documented research limitation.


3. Evidence for Use in Managing Acute Hypercalcemia

Caltec was evaluated in studies focusing on acute, pathologically high blood calcium levels (hypercalcemia). Researchers primarily tracked the rate and magnitude of reduction in serum calcium levels over very short, defined time intervals. The data show patterns related to a quick initial change in serum calcium levels. However, research indicates that long-term data are insufficient to describe use beyond the initial, acute phase.

Key Studies & References Calcitonin: properties and mechanisms of action

Frequently Asked Questions (FAQ)

Common questions about Caltec (FAQ)

Q: What is the main reason Caltec is prescribed by doctors?

According to official product information, Caltec is approved for treating specific conditions related to bone and mineral metabolism. These include postmenopausal osteoporosis, Paget's Disease of Bone, and certain cases of high blood calcium levels (hypercalcemia) when a rapid reduction in calcium is necessary.

Q: Is Caltec a painkiller or a treatment for a specific condition?

Caltec is a synthetic peptide hormone that works by suppressing the body's bone breakdown process (resorption), meaning it is primarily a treatment for specific bone conditions. Clinical data also indicates that it may provide relief for acute pain associated with recent vertebral fractures in certain approved uses.

Q: How quickly does Caltec usually start to work?

Official documents indicate that for acute conditions, such as high blood calcium levels (hypercalcemia), the onset of action may be observed as early as 6 to 8 hours. However, the full therapeutic effect when treating chronic bone diseases, like osteoporosis or Paget’s disease, may take a longer period of time to become apparent.

Q: Can Caltec affect my ability to drive or operate machinery?

Yes, the official product information advises caution because Caltec may cause temporary side effects such as dizziness, tiredness, or disturbed vision, which have the potential to impair reactions. If these effects occur, official safety documentation suggests caution when driving or operating machinery.

Q: How long can a person safely stay on Caltec treatment?

Regulatory guidance states that the total duration of treatment should be limited to the shortest possible time. This is due to a possible increased risk of malignancy (cancer) that has been noted with long-term use (exceeding one year). The need for continued therapy is typically subject to careful, periodic re-evaluation by a healthcare professional.

Q: Are the side effects of Caltec usually temporary?

Official product information indicates that some of the most common side effects, such as flushing of the face and nausea, are often most prominent when treatment is first started. These specific effects typically tend to lessen or disappear as treatment continues.

Q: Are there specific symptoms that signal a serious side effect from Caltec?

Yes, regulatory documents list symptoms that may indicate a serious allergic reaction, known as anaphylaxis. These can include difficulty breathing, swelling of the throat or tongue, a rapid heartbeat, or the sudden appearance of hives. If any of these symptoms occur, these situations warrant immediate medical attention.

Q: Are there any common lab tests required while taking Caltec?

Official safety information recommends the monitoring of serum calcium levels, along with observing for any symptoms of low calcium (hypocalcemia). Additionally, periodic examinations of urine sediment may be considered as part of the ongoing monitoring.

Q: How does Caltec affect energy levels or sleep?

The adverse reactions section in official product documents lists unusual tiredness or weakness and trouble sleeping (insomnia) as reported side effects. However, the exact frequency with which these issues affect patients is not known based on the available clinical data.

Q: What is the difference between an allergy to Caltec and a side effect?

Official medical documentation separately addresses hypersensitivity reactions (allergic reactions) and adverse reactions (side effects). Hypersensitivity, including serious reactions like anaphylaxis, is defined as a contraindication. Adverse reactions are other documented, less severe effects like nausea that may occur during treatment.

Q: How does the body eliminate Caltec?

According to pharmacokinetic data, the medicine is primarily degraded in the kidneys. The resulting substances are then eliminated from the body through the urine.

Q: Why does Caltec have warnings about pre-existing heart conditions?

Warnings exist regarding the use of this medicine in combination with certain heart medications, specifically Cardiac Glycosides and Calcium Channel Blocking Agents. This is because the medicine affects mineral dynamics and may modify the effects of those agents through changes in cellular electrolyte concentrations.

Q: Why do some patients feel better right away on Caltec, but others do not?

Regulatory documents note that some patients may develop circulating antibodies to calcitonin salmon, the active ingredient. This antibody formation can cause a patient who initially responded well to treatment to later experience a diminished or ceased response.

Q: Is Caltec affected by kidney or liver function?

The medicine is primarily processed by the kidneys, and official documents note that reduced metabolic clearance occurs in patients with end-stage renal failure. Furthermore, regulatory documents advise caution for patients who have pre-existing kidney or liver problems.

Q: Is Caltec known to cause weight gain or weight loss?

The adverse reactions section in official product documents lists both unusual weight gain and weight loss as reported effects. However, it is noted that the frequency of these particular effects is not known based on the available clinical data.

Q: What happens if I forget to take Caltec for one day?

Regulatory patient information describes how to handle a missed dose, typically by administering it as soon as it is remembered. However, if it is almost time for the next scheduled dose, only that scheduled dose should be administered, and double or extra doses are generally not recommended.

Q: Is it normal to feel tired when starting Caltec?

The official list of adverse reactions includes unusual tiredness or weakness. While this effect has been reported, the frequency with which it occurs is not known from the available clinical data.

Q: Has Caltec been studied in children or adolescents?

Official product documentation states that the medicine is not indicated for use in children or adolescents. Consequently, there is limited clinical data available regarding its use in the pediatric population.

Q: Can Caltec be used during pregnancy or while breastfeeding?

Official regulatory information states that the medicine is not indicated for women of reproductive potential, and there are no adequate data regarding its use during pregnancy. It is further noted that the medicine inhibits lactation in animal studies, and therefore, breastfeeding is generally not recommended.

Q: Is Caltec a type of antibiotic or steroid?

No, Caltec is not a type of antibiotic used to fight infections, nor is it a steroid. The active ingredient is a synthetic peptide hormone that targets specific receptors involved in bone metabolism.

Q: Can Caltec affect fertility in men or women?

The product is not indicated for females of reproductive potential. In animal studies, the medicine has been shown to inhibit lactation, and caution is advised regarding its use for women of childbearing age.

Q: Does Caltec interact with common pain relievers like ibuprofen?

Formal studies designed to test drug interactions have not been widely performed by the manufacturer. However, the regulatory interaction section lists specific medicines but does not mention common pain relievers such as ibuprofen.

Q: Is it okay to stop taking Caltec suddenly?

Official patient labeling indicates that treatment discontinuation should generally not be sudden. Consultation with a healthcare professional is standard procedure before making any changes to a medication schedule.

How should Caltec be stored and disposed of?

The official regulatory guidelines for Caltec (Calcitonin Salmon) mandate strict storage conditions. Unopened packages of both the Solution for Injection and the Nasal Spray must be stored under refrigeration between 2 C and 8 C and must not be frozen. The injection solution should also be protected from light.

Stability rules are form-specific: once punctured, the injection vial must be discarded after 14 days; the opened nasal spray must be discarded after 30 days. Both forms can be stored at room temperature (20 C to 25 C) during their in-use period. The medication must be kept out of the sight and reach of children.

Disposal must be completed according to local regulations for pharmaceutical waste, and the product must not be discarded via wastewater or general household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caltec found in:

A-Z Index: